Abstract

The fish acute toxicity test (TG203; OECD, 2019) is frequently used and highly embedded in hazard and risk assessment globally. The test estimates the concentration of a chemical that kills 50% of the fish (LC50) over a 96 h exposure and is considered one of the most severe scientific procedures undertaken. Over the years, discussions at the Organisation for Economic Co-operation and Development (OECD) have resulted in changes to the test which reduce the number of fish used, as well as the development of a (potential) replacement test (TG236, OECD, 2013). However, refinement of the mortality endpoint with an earlier (moribundity) endpoint was not considered feasible during the Test Guideline’s (TG) last update in 2019. Several stakeholders met at a UK-based workshop to discuss how TG203 can be refined, and identified two key opportunities to reduce fish suffering: (1) application of clinical signs that predict mortality and (2) shortening the test duration. However, several aspects need to be addressed before these refinements can be adopted. TG203 has required recording of major categories of sublethal clinical signs since its conception, with the option to record more detailed signs introduced in the 2019 update. However, in the absence of guidance, differences in identification, recording and reporting of clinical signs between technicians and laboratories is likely to have generated piecemeal data of varying quality. Harmonisation of reporting templates, and training in clinical sign recognition and recording are needed to standardise clinical sign data. This is critical to enable robust data-driven detection of clinical signs that predict mortality. Discussions suggested that the 96 h duration of TG203 cannot stand up to scientific scrutiny. Feedback and data from UK contract research organisations (CROs) conducting the test were that a substantial proportion of mortalities occur in the first 24 h. Refinement of TG203 by shortening the test duration would reduce suffering (and test failure rate) but requires a mechanism to correct new results to previous 96 h LC50 data. The actions needed to implement both refinement opportunities are summarised here within a roadmap. A shift in regulatory assessment, where the 96 h LC50 is a familiar base for decisions, will also be critical.

Highlights

  • The fish acute toxicity test is a frequently used test for chemical hazard characterisation (Burden et al, 2017, 2020) and is strongly embedded in the risk assessment of chemicals globally

  • Discussions at the Organisation for Economic Co-operation and Development (OECD) have resulted in changes to the test which reduce the number of fish used, as well as the development of a replacement test (TG236, Organisation for Economic Cooperation and Development (OECD), 2013)

  • The test was originally adopted as an Organisation for Economic Cooperation and Development (OECD) test guideline (TG203) in 1981

Read more

Summary

Introduction

The fish acute toxicity test is a frequently used test for chemical hazard characterisation (Burden et al, 2017, 2020) and is strongly embedded in the risk assessment of chemicals globally. A key refinement method in mammalian testing is the use of evident toxicity in place of death as the endpoint: the range estimate of the LC50/LD50 is predicted based on clear signs of toxicity at a lower dose/ concentration, using biometrical evaluation tools and/or observations of clinical signs to assess evident toxicity in individual animals as an endpoint (OECD TG402, 433, Mielke et al, 2017; Sewell et al, 2015, 2018) This refinement reduces animal suffering and was accepted in the revised acute oral toxicity (TG420) in 2002 and in the revised inhalation (TG433) and dermal routes (TG402) in 2017. To identify a viable mechanism by which data from TG203 tests conducted internationally can be collected and stored to support analysis of linkages between sublethal clinical signs, moribundity and death, and chemical mode of action

The origin of TG203
The current regulatory context
Is TG203 fit for purpose?
Refinement opportunities for TG203
Evidence base needs on moving away from mortality as an endpoint
Evidence based needs for reducing the test duration
Findings
Workshop recommendations
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call